Mepro Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 5.40 Cr
as on 22-06-2024
- Paid Up Capital ₹ 5.35 Cr
as on 22-06-2024
- Company Age 42 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 169.20 Cr
as on 22-06-2024
- Satisfied Charges ₹ 12.50 Cr
as on 22-06-2024
- Revenue -6.58%
(FY 2022)
- Profit 14.73%
(FY 2022)
- Ebitda -9.41%
(FY 2022)
- Net Worth 12.02%
(FY 2022)
- Total Assets -0.95%
(FY 2022)
About Mepro Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.40 Cr and a paid-up capital of Rs 5.35 Cr.
The company currently has active open charges totaling ₹169.20 Cr. The company has closed loans amounting to ₹12.50 Cr, as per Ministry of Corporate Affairs (MCA) records.
Bharatkumar Shah, Rajesh Shah, Prakash Shah, and Two other members serve as directors at the Company.
- CIN/LLPIN
U24231GJ1982PTC005451
- Company No.
005451
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
31 Aug 1982
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Surendra Nagar, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Mepro Pharmaceuticals?
Board Members(5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rajesh Shah  | Director | 30-Sep-1987 | Current |
| Bharatkumar Shah | Director | 31-Aug-1982 | Current |
| Prakash Shah | Director | 17-Jul-2004 | Current |
| Suresh Shah | Director | 31-Aug-1982 | Current |
| Vijay Shah | Whole-Time Director | 31-Aug-1982 | Current |
Financial Performance of Mepro Pharmaceuticals.
Mepro Pharmaceuticals Private Limited, for the financial year ended 2022, experienced Minor drop in revenue, with a 6.58% decrease. The company also saw a substantial improvement in profitability, with a 14.73% increase in profit. The company's net worth Soared by an impressive increase of 12.02%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Mepro Pharmaceuticals?
In 2021, Mepro Pharmaceuticals had a promoter holding of 22.59% and a public holding of 77.41%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Sunshine Organics Pvt LtdActive 36 years 2 monthsBharatkumar Shah and Rajesh Shah are mutual person
Mepromax Life Sciences Private LimitedActive 19 years 8 monthsBharatkumar Shah, Rajesh Shah and 2 more are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 05 Dec 2022 | ₹5.00 Cr | Open |
Others Creation Date: 17 Oct 2019 | ₹38.50 Cr | Open |
Yes Bank Limited Creation Date: 17 Oct 2019 | ₹10.00 Cr | Open |
How Many Employees Work at Mepro Pharmaceuticals?
Mepro Pharmaceuticals has a workforce of 516 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Mepro Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Mepro Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
